2015

PHOENIX group reaffirms its position as a leading healthcare provider in Europe

The PHOENIX group underlined its position as a leading healthcare provider in Europe in the first three quarters of the fiscal year 2015/16. The company’s overall performance in the European market continued developing very positively. Total operating performance, including revenue as well as...

read more
PHOENIX group substantiates its leading position as a healthcare provider in Europe

The PHOENIX group underlined its position as a leading healthcare provider in Europe in the first half of the fiscal year 2015/16. The company’s overall performance in the European market continued developing very positively. Total operating performance, which includes revenue as well as handled...

read more
PHOENIX group receives approval for acquisition of SUNPHARMA

The appropriate competition authorities have unconditionally approved the acquisition of the Slovakian company SUNPHARMA by the PHOENIX group. The PHOENIX group had announced the acquisition of SUNPHARMA back in January 2015 – subject to approval by the antitrust authorities. The company operates 42...

read more
PHOENIX group underlines its position as a leading healthcare provider in Europe

The PHOENIX group consolidated its position as a leading healthcare provider in Europe in the first quarter of the fiscal year 2015/16. The company’s overall performance in Europe exceeded that of the market as a whole. Total operating performance, including revenue as well as handled volume for...

read more
Leading market position in Europe expanded

The PHOENIX group brought the fiscal year 2014/15 to a successful close, expanding its position as a leading healthcare provider in Europe despite the challenging European market environment. Total operating performance, including revenue as well as handled volume (handling for service charge), rose...

read more
PHOENIX group strengthens its position in the Hungarian healthcare market

The PHOENIX group intends to acquire the Hungarian company Novodata. The acquisition is subject to approval by the relevant competition authorities. Since its founding in 1988, Novodata has been successfully operating in the Hungarian healthcare market with its pharmacy software and is now the...

read more
PHOENIX celebrates its 20th anniversary

The PHOENIX group is celebrating the company’s 20th anniversary today. In 1994, Adolf Merckle founded PHOENIX Pharmahandel Aktiengesellschaft & Co from the German regional wholesalers F. Reichelt AG in Hamburg, Otto Stumpf GmbH in Berlin, Ferdinand Schulze GmbH & Co. in Mannheim, Otto Stumpf AG in...

read more
PHOENIX group strengthens its market position as an integrated healthcare provider

PHOENIX plans to acquire the Slovakian company SUNPHARMA, which operates 42 pharmacies in Slovakia and eight in the Czech Republic. The pharmacies are located in prime areas such as shopping centres. The acquisition is subject to approval by the relevant competition authorities. The parties have...

read more

2014

PHOENIX group once again increases revenue and profit for the period in third quarter of 2014/15

The PHOENIX group underlined its position as Europe’s leading pharmaceutical trader in the first three quarters of 2014/15. “We are pleased with the development – the improved results of operations in Western and Northern Europe in particular confirm that we are heading in the right direction.

read more
PHOENIX and Celesio jointly strengthen their market position in the Netherlands

The planned purchase will make Brocacef a leading service provider in the Dutch healthcare market. With a total of 5,300 employees and revenue of EUR 2.1 billion, Brocacef continues to expand its range, and by acquiring the pre-wholesale activities, it will be able to offer more comprehensive...

read more
PHOENIX group with higher revenue and stable profit for the period in the first half of 2014/15

The PHOENIX group consolidates its position in Europe as leading pharmaceutical trader in the first half of 2014/15. “We are pleased with the development in the first half of 2014/15, and our success is confirmed in particular by the improved results of operations in Western and Northern Europe”,...

read more
PHOENIX group issues corporate bond with a volume of EUR 300 million

The PHOENIX group is taking advantage of the current attractive market environment and has successfully issued another corporate bond. This bond marks the third successful emission by the pharmaceutical trader. After the issuance of the inaugural bond in July 2010, the PHOENIX group strengthened its...

read more
1st quarter 2014/15: revenue growth is continuing

The PHOENIX group underlined its position as Europe’s leading pharmaceutical trader in the first quarter of the fiscal year 2014/15. Revenue increased by 2.1 per cent compared with the same period of the previous year to EUR 5,452.0 million in the first quarter of 2014/15.

read more
Leading market position in Europe confirmed

The PHOENIX group continued to secure its position as Europe’s leading pharmaceutical trader in the fiscal year 2013/14, despite the challenging European market environment. Revenue rose by 2.7 per cent to EUR 21,792.4 million. This was due to the higher revenues in Finland, Italy, the Netherlands,...

read more

2013

Growth trend continued in third quarter of 2013/14

The PHOENIX group once again underlined its position in Europe as leading pharmaceutical trader in the first three quarters of the 2013/14 fiscal year. Revenue increased by 2.8 per cent (3.6 per cent after adjustment for exchange rate effects) compared with the same period of the previous year to...

read more
PHOENIX strengthens organizational structure in Germany

Today the PHOENIX group has announced several planned organizational changes in the structure of PHOENIX in Germany. These measures are part of the group-wide optimization programme PHOENIX FORWARD initiated in January 2013 which aims to achieve annual cost savings of EUR 100 million Europe-wide.

read more
Reimund Pohl retires effective from 31 January 2014

Reimund Pohl, Chief Executive Officer of PHOENIX Pharmahandel GmbH & Co KG (PHOENIX group), will retire as scheduled by the end of the fiscal year 2013/14 on 31 January 2014 after having worked for the company for 32 years. Effective from 1 February 2014, Oliver Windholz, Executive Board Member for...

read more
Significant revenue growth in the 1st half of the year despite negative market developments in Europe

The PHOENIX group underlines its position as Europe’s leading pharmaceutical trader in the first half of 2013/14. “In the first half of 2013/14 we performed well in a persistently challenging market environment, with business developing particularly well in Northern and Eastern Europe”, said Reimund...

read more
Personnel change in the PHOENIX group Executive Board

Dr. Michael Majerus, CFO of PHOENIX Pharmahandel GmbH & Co KG (PHOENIX group), responsible for finance, controlling, accounting and taxes will leave the company effective from 31. August 2013 by mutual consent after having successfully implemented a new financing structure in the PHOENIX group. Dr....

read more
Revenue in first quarter of 2013/14 increased in line with expectations

The PHOENIX group underlines its position as a leading pharmaceutical trader in Europe on the basis of its dynamic business development in the first quarter of the 2013/14 fiscal year. In the first quarter of 2013/14, revenue increased by 2.7 per cent compared with the same period of the previous...

read more
PHOENIX group issues corporate bonds with a volume of EUR 300 million

PHOENIX group is taking advantage of the current attractive market environment and has – following its inaugural bond in July 2010 – successfully issued another corporate bond. More than 100 investors were met during a very well-received pan-European road show in Frankfurt am Main, London, Paris,...

read more
Successful completion of 2012/13 fiscal year

The PHOENIX group ends the 2012/13 fiscal year on a positive note despite a challenging European market environment. The company has further extended its position as a leading pharmaceutical trader in Europe. Revenue only experienced a moderate decline of 2 per cent to EUR 21,218.7 million compared...

read more
PHOENIX group initiates the “PHOENIX FORWARD” program

With its sustainable growth strategy the PHOENIX group has positioned itself as leading pharmaceutical distributor in Europe. “The PHOENIX group can proudly look back on the highly successful development of its business operations.

read more
Press contacts
PHOENIX group Ingo Schnaitmann
Ingo Schnaitmann Head of Corporate Communications +49 621 8505 8593 i.schnaitmann(at)phoenixgroup.eu
PHOENIX group Jacob-Nicolas Sprengel
Jacob-Nicolas Sprengel Senior Manager Corporate Communications +49 621 8505 8502 j.sprengel(at)phoenixgroup.eu